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Background: Oxaliplatin, an important chemotherapy drug for advanced colorectal cancer, often induces
peripheral neuropathy, especially cold allodynia. Our previous study showed that bee venom acupuncture (BVA),
which has been traditionally used in Korea to treat various pain symptoms, potently relieves oxaliplatin-induced
cold allodynia in rats. However, the mechanism for this anti-allodynic effect of BVA remains poorly understood. We
investigated whether and how the central serotonergic system, a well-known pathway for acupuncture analgesia,
mediates the relieving effect of BVA on cold allodynia in oxaliplatin-injected rats.
Methods: The behavioral signs of cold allodynia in Sprague–Dawley (SD) rats were induced by a single injection of
oxaliplatin (6 mg/kg, i.p.). Before and after BVA treatment, the cold allodynia signs were evaluated by immersing the
rat’s tail into cold water (4°C) and measuring the withdrawal latency. For BVA treatment, a diluted BV (0.25 mg/kg)
was subcutaneously administered into Yaoyangguan (GV3) acupoint, which is located between the spinous processes
of the fourth and the fifth lumbar vertebra. Serotonin was depleted by a daily injection of DL-p-chlorophenylalanine
(PCPA, 150 mg/kg, i.p.) for 3 days. The amount of serotonin in the spinal cord was measured by ELISA. Serotonergic
receptor antagonists were administered intraperitoneally or intrathecally before BVA treatment.
Results: The serotonin levels in the spinal cord were significantly increased by BVA treatment and such increase was
significantly reduced by PCPA. This PCPA pretreatment abolished the relieving effect of BVA on oxaliplatin-induced cold
allodynia. Either of methysergide (mixed 5-HT1/5-HT2 receptor antagonist, 1 mg/kg, i.p.) or MDL-72222 (5-HT3 receptor
antagonist, 1 mg/kg, i.p) blocked the anti-allodynic effect of BVA. Further, an intrathecal injection of MDL-72222 (12 μg)
completely blocked the BVA-induced anti-allodynic action, whereas NAN-190 (5-HT1A receptor antagonist, 15 μg, i.t.) or
ketanserin (5-HT2A receptor antagonist, 30 μg, i.t.) did not.
Conclusions: These results suggest that BVA treatment alleviates oxaliplatin-induced acute cold allodynia in rats via
activation of the serotonergic system, especially spinal 5-HT3 receptors. Thus, our findings may provide a clinically useful
evidence for the application of BVA as an alternative therapeutic option for the management of peripheral neuropathy,
a dose-limiting side effect that occurs after an administration of oxaliplatin.
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Oxaliplatin, a third-generation platinum-based chemo-
therapy agent, is considered a central component in the
treatment of advanced colorectal cancer [1,2]. The most
important side effect of oxaliplatin treatment is a periph-
eral neuropathy that has unique characteristics and repre-
sents a major dose-limiting toxicity [3,4]. This unpleasant
acute neurosensory toxicity with dysesthesia of the distal
extremities and perioral region occurs shortly after an
infusion in as much as 90% of the patients. These symp-
toms can be worsened or triggered by cold [5-7]. However,
the mechanisms and the effective treatment for oxaliplatin-
induced cold allodynia still remain to be elucidated [8].
Therefore it is worth searching for potential therapeutic
options for the management of oxaliplatin-induced neuro-
pathic pain and revealing their action mechanisms.
Bee venom acupuncture (BVA), a kind of chemical
stimulation of peripheral nerves (i.e. a subcutaneous injec-
tion of diluted BV into one or more acupoints) [9], has
long been used in Korea, to relieve pain and to treat
inflammatory diseases such as rheumatoid arthritis and
osteoarthritis [10-12]. Several animal studies have demon-
strated that the analgesic effects of BVA are mediated
mainly by activation of α2-adrenergic and/or serotonergic
receptors in various pain models, such as nerve injury-
induced neuropathic pain, acetic acid-induced visceral
pain and inflammatory pain [12-15]. In our recent study
[16], we showed that BVA (0.25 mg/kg) treatment at
Yaoyangguan (GV3) acupoint significantly attenuated
oxaliplatin-induced cold allodynia in rats, which was
greater than BVA treatment at the other well-known acu-
points for acupuncture analgesia (e.g. Zusanli [ST36] and
Quchi [LI11]). However, this anti-allodynic action of BVA
was only partially mediated by the noradrenergic system
[16]. In addition, the endogenous opioid system that
plays a key role in mediating electroacupuncture (EA)-
induced anti-allodynia in oxaliplatin-injected rats [17]
was not involved in such BVA effect [16]. These results
suggest that another analgesic system might be respon-
sible for the relieving effect of BVA on oxaliplatin-
induced neuropathic cold allodynia.
The present study was performed to examine whether
the suppressive effect of BVA on cold allodynia in
oxaliplatin-injected rats is mediated by the serotonergic
inhibitory system, which has been regarded as one of
the major non-opioid anti-allodynic pathway for acu-
puncture or EA [18,19]. We further investigated which
subtype of serotonergic receptors is specifically impli-
cated in BVA-induced anti-allodynic action. We report
here that BVA treatment exerts its strong relieving
effect on oxaliplatin-induced cold allodynia mainly via the
activation of spinal 5-HT3 receptors, providing a basic evi-
dence for the use of BVA treatment in the management of
peripheral neuropathy in oxaliplatin-administered subjects.Methods
Animals
Young adult male Sprague–Dawley rats [Sam:TacN(SD)
BR, 200-220 g, 7 weeks old] were housed in cages (3–4
rats per cage) with water and food available ad libitum.
The room was maintained with a 12 h-light/dark cycle
(a light cycle; 08:00–20:00, a dark cycle; 20:00–08:00) and
kept at 23 ± 2°C. All animals were acclimated in their
cages for 1 week prior to any experiments. All procedures
involving animals were approved by the Institutional
Animal Care and Use Committee of Kyung Hee University
(KHUASP(SE)-14-010) and were conducted in accordance
with the guidelines of the International Association for the
Study of Pain [20].
Oxaliplatin injection
As described previously [21,22], oxaliplatin (Sigma, St
Louis, MO, USA) was dissolved in a 5% glucose (Sigma)
solution at a concentration of 2 mg/mL and was intra-
peritoneally administered at 6 mg/kg. The same volume
of 5% glucose solution was injected in the vehicle con-
trol group.
Behavioral test
To estimate whether cold allodynia was induced, cold
immersion test was carried out as described previously
[18,23,24]. Briefly, each animal was lightly immobilized
in a plastic holder and its tail was drooped for a proper
application of cold water stimuli. The rats were adapted
to the holder for 2 days before starting behavioral tests.
The tail was immersed in 4°C water, and then the tail
withdrawal latency (TWL) was measured with a cut-off
time of 15 seconds. The cold immersion test was
repeated five times at 5 min intervals. When calculating
the average latency, the cut-off time was assigned to the
normal responses. The average latency was taken as a
measure for the severity of cold allodynia; a shorter
TWL was interpreted as more severe allodynia.
Because our previous study [17] showed that a signifi-
cant cold allodynia sign is induced from 3 days after a
single oxaliplatin (6 mg/kg, i.p.) injection and lasted up
to 1 week after an injection, we tested whether and how
the serotonergic system mediates the relieving effect of
BVA on cold allodynia from 3 to 7 days after an oxalipla-
tin administration. In general, we replicated the experi-
ments twice.
BVA treatment
We previously showed that the optimal acupoint of
BVA-induced anti-allodynia in oxaliplatin-injected rats is
Yaoyangguan (GV3) acupoint, and that low doses of
BVA (0.25 mg/kg and 1.0 mg/kg) at GV3 is more effect-
ive than a high dose of BVA (2.5 mg/kg) [16]. Thus, in
this study, BV (0.25 mg/kg) dissolved in normal saline
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point, which is located between the spinous processes of
the fourth and the fifth lumbar vertebrae [25]. To the
control group, only 0.05 cc of N/S was injected subcuta-
neously at the same acupoint.
After baseline cold sensitivity was measured, BV
(0.25 mg/kg) and N/S were injected subcutaneously at
GV3, respectively. The cold immersion test was per-
formed again at 30 min after BVA.Depletion of serotonin
Rats were intraperitoneally administered with DL-p-
chlorophenylalanine (PCPA, Sigma, an inhibitor of sero-
tonin synthesis, 150 mg/kg/day) or vehicle (N/S) for three
days. The dosage and treatment course of PCPA has been
widely used to deplete 5-HT stores [26,27]. On the day
after the final injection of PCPA, oxaliplatin was adminis-
terd as described.Antagonists
Oxaliplatin-injected rats were divided randomly into
four groups: N/S + BV (n = 7), DMSO + BV (n = 4),
methysergide + BV (n = 7), and MDL-72222 + BV (n = 7).
Methysergide maleate (mixed 5-HT1/5-HT2 receptor
antagonist) and 3-tropanyl-3,5-dichlorobenzoate (MDL-
72222, 5-HT3 receptor antagonist) were dissolved in N/S
or 20% dimethyl sulfoxide (DMSO) to a concentration
of 1 mg/ml. After baseline cold sensitivity was checked,
the four groups were treated intraperitoneally with N/S,
20% DMSO, methysergide (1 mg/kg) and MDL-72222
(1 mg/kg), respectively. Twenty minutes later, all groups
were treated subcutaneously with 0.25 mg/kg of BV at
GV3 acupoint. The cold immersion test was performed
again 30 min after BVA.
To further identify which spinal serotonergic receptor
subtypes mediate BVA-induced anti-allodynia, oxaliplatin-
injected rats in a different set of experiments were divided
randomly into five groups: N/S + BV (n = 7), DMSO+ BV
(n = 3), NAN-190 + BV (n = 8), ketanserin + BV (n = 8),
and MDL-72222 + BV (n = 8). Ketanserin tartrate (5-HT2A
receptor antagonist, 30 μg) was dissolved in 50 μl N/S.
1-(2-methoxyphenyl)-4-(4-[2-phthalimido]butyl) piperazine
hydrobromide (NAN-190, 5-HT1A receptor antagonist,
15 μg), and MDL-72222 (12 μg) were dissolved in 50 μl
20% DMSO. Drugs were administered intrathecally
under isoflurane anesthesia with the direct lumbar
puncture as described previously [28]. Briefly, 50 μl of
an antagonist was injected through the L3-L4 interver-
tebral space, which successfully delivers the drugs to the
lower lumbar and sacral spinal cord segments. BVA was
performed at 10 min after the intrathecal injection of an
antagonist and the cold immersion test was performed
again 30 min after BVA.All drugs were obtained from Tocris Cookson, UK.
The doses of antagonists were selected based on previ-
ously published studies that show selectivity for the indi-
vidual receptor subtypes [18,29-32].
ELISA
To investigate whether BV treatment increases the quan-
tity of serotonin and whether PCPA decreases that, rats
were divided randomly into three groups: Vehicle +N/S,
Vehicle + BV, and PCPA + BV (n = 5/group). All the
animals having oxliplatin-induced cold allodynia signs
were sacrificed 30 minutes after BV or N/S treatment,
and the lumbar spinal cords of L4 ~ L5 were extracted
out on an ice-cold Petri dish as per Glowinski and
Iversen [33] and stored at −70°C until the day of ana-
lysis. The amount of total protein in the spinal cord
samples was measured with the PCA protein assay
(PIERCE, USA). Serotonin contents were quantified
with the rat 5-HT ELISA kit (LDN, Germany: Catalogue
No. BA E-5900; Sensitivity, 0.005 ng/ml; Specificity,
100% cross-reactivity for serotonin) according to the
manufacturer’s instructions.
Statistical analysis
All the data are presented as mean ± SEM. Statistical
analysis was done with Prism 5.0 (Graph Pad Software,
USA). Paired t-test or one-way ANOVA followed by
Dunnett’s multiple comparison test was used for statistical
analysis. In all cases, p < 0.05 was considered significant.
Results
Effects of 5-HT depletion with PCPA on BVA-induced
anti-allodynia in oxaliplatin-injected rats
To determine whether the serotonergic system is involved
in the anti-allodynic effect of BVA, we evaluated the effect
of depletion of central 5-HT by PCPA on the BVA effect.
As shown in Figure 1a, the levels of 5-HT in the spinal
cord measured by ELISA were significantly increased
after BVA treatment at GV3 (p < 0.01, Vehicle + N/S vs.
Vehicle + BV). This marked increase in spinal 5-HT
levels by BVA was significantly blocked by PCPA pre-
treatment (p < 0.05, Vehicle + BV vs. PCPA + BV). We
also confirmed the depletion of 5-HT in the hypothal-
amus by PCPA (data not shown). These results indicate
that BVA treatment markedly increases the amount of
central 5-HT, especially in the spinal cord, and PCPA
prevents such 5-HT increase by BVA.
Figure 1b shows the effect of 5-HT depletion on the
relieving effect of BVA on cold allodynia in oxaliplatin-
injected rats. The control group (vehicle (N/S) pretreat-
ment) showed a significant increase in TWL after BVA
treatment (p < 0.001), whereas the depletion of 5-HT by
PCPA pretreatment blocked the anti-allodynic effect of
BVA (p > 0.05). These results suggest that the serotonergic
Figure 1 Effects of PCPA on BVA-induced increases in 5-HT and TWL in oxaliplatin-injected rats. (a) Levels of 5-HT in the spinal cord
measured with ELISA. Vehicle + N/S, Vehicle + BV, and PCPA+ BV (n = 5/group). Data are presented as mean ± SEM. *p < 0.05, **p < 0.01, by one-way
ANOVA followed by Dunnet’s test. (b) PCPA, but not vehicle pretreatment (n = 8/group), blocked the significant increase in TWL by BVA at GV3
acupoint. Data are presented as mean ± SEM. ***p < 0.001, ns = no significant, by paired t-test.
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effect of BVA on oxaliplatin-induced cold allodynia.
Effects of serotonergic receptor antagonists on BVA-induced
anti-allodynia in oxaliplatin-injected rats
To investigate which subtype of serotonergic receptors is
specifically implicated in the relieving effect of BVA on
oxaliplatin-induced cold allodynia, we first tested the
effects of a systemic injection of methysergide (mixed
5-HT1 /5-HT2 receptor antagonist, 1 mg/kg, i.p.) or
MDL-72222 (5-HT3 receptor antagonist, 1 mg/kg, i.p.)
on BVA-induced anti-allodynia. As shown in Figure 2,
the N/S or 20% DMSO control group showed a signifi-
cant increase in TWL after BVA treatment (p < 0.01),
whereas both experimental groups (methysergide or
MDL-72222 pretreated group) exhibited no significant
difference in TWL before and after BVA (p > 0.05).
We further confirmed that an intrathecal injection of
MDL-72222 (12 μg) completely blocked the BVA-induced
anti-allodynic action in oxaliplatin-injected rats (p > 0.05,
Figure 3d). However, as similar to the N/S or 20% DMSO
control group, an intrathecal administration of NAN-190
(5-HT1A receptor antagonist, 15 μg) or ketanserin (5-HT2AFigure 2 Effects of systemic injection of 5-HT antagonists on BVA-ind
were performed before an intraperitoneal injection of antagonists and afte
and DMSO+ BV (right, n = 4), (b) methysergide + BV, and (c) MDL-72222+ BV (
ns = no significant, by paired t-test.receptor antagonist, 30 μg) did not block the anti-allodynic
effect of BVA (Figure 3a-c). These results suggest that BVA
alleviates cold allodynia in oxaliplatin-injected rats mainly
via the activation of spinal 5-HT3 receptors.
Discussion
Oxaliplatin, an important chemotherapy drug active
against colorectal cancer [1,2], induces peripheral neur-
opathy triggered or aggravated in cold conditions even
after a single administration [21,22]. There are few
researches showing the effective treatment for the
established neuropathic pain induced by oxaliplatin [8].
The potential therapeutic options are thus critically
needed to manage this neuropathic pain for helping the
patients overcome cancer and improving their quality of
life. Our previous study demonstrated for the first time
that BVA has a potent relieving effect on oxaliplatin-
induced cold allodynia in rats.
Unlike the EA-induced analgesia mainly involving the
endogenous opioid system, the analgesic effects of BVA
are known to be mediated by the non-opioid, descending
noradrenergic system [12,15,34,35]. We recently demon-
strated that EA significantly attenuates oxaliplatin-induceduced anti-allodynic action. The behavioral tests for cold allodynia
r BVA treatment in the four groups of animals: (a) N/S + BV (left, n = 7)
n = 7/group). Data are presented as mean ± SEM. **p< 0.01, ***p< 0.001,
Figure 3 Effects of intrathecal injection of 5-HT antagonists on BVA-induced anti-allodynic action. The behavioral tests for cold allodynia
were performed before an intrathecal injection of antagonists and after BVA treatment in the five groups of animals: (a) N/S + BV (left, n = 7) and
DMSO + BV (right, n = 3), (b) NAN-190 + BV, (c) ketanserin + BV, and (d) MDL-72222 + BV (n = 8/group). Data are presented as mean ± SEM (bar
graph) and individual traces in TWL change. *p < 0.05, **p < 0.01, ns = no significant, by paired t-test.
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opioids, not the noradrenergic system [17]. However,
the anti-allodynic effect of BVA in the same rat model was
shown to be only partially mediated by the noradrenergic
analgesic system [16]. Therefore, the neurochemical mech-
anism of the BVA effect on oxaliplatin-induced neuro-
pathic pain still remains unclear.
In the present study, we focused on the other non-
opioid analgesic pathway, the serotonergic inhibitory
system. This serotonergic system is one of the well-known
non-opioid mediators for acupuncture or EA analgesia
[19] and a study by Lee and his colleagues reported that
the descending serotonergic system is also involved in the
antinociceptive effect of BVA in the rat formalin pain
model [14]. In the present study, we observed that BVA
treatment significantly increases the levels of spinal 5-HT
and the TWL in oxaliplatin-injected rats. Such BVA effects
were blocked by PCPA depletion of 5-HT (Figure 1). This
implies that BVA exerts a potent analgesic effect on
oxaliplatin-induced cold allodynia by activating the spinal
serotonergic inhibitory system.
It has been known that spinal administration of 5-HT
produces analgesic effects, depending on the receptor
type activated and dosage use [36-38]. And the analgesic
effect of serotonin is reported to be mediated by the
descending pain inhibitory system from periaqueductal
grey, nucleus raphe magnus and finally spinal serotoner-
gic receptors [39,40]. Among the several subtypes of
serotonin receptors (5-HT1–7), 5-HT1, 5-HT2 and 5-HT3
receptors are known to be the most commonly implicated
in spinal pain processing [32,41,42]. In this study, a
systemic injection of methysergide (mixed 5-HT1/5-HT2
receptor antagonist) or MDL-72222 (5-HT3 receptor
antagonist) prevented the relieving effect of BVA on cold
allodynia (Figure 2). Our additional experiments (Figure 3)
further showed that the BVA effect was blocked only by
an intrathecal injection of MDL-72222, but not by an
intrathecal injection of NAN-190 (5-HT1A receptor an-
tagonist) or ketanserin (5-HT2A receptor antagonist).
The discrepancy in the results between systemic and
intrathecal administration of antagonists might be dueto the use of non-selective antagonist, methysergide for
the systemic injection experiment. Also, individual dif-
ferences in the sensitivity of the rats to intrathecal
NAN-190 or ketanserin might contribute to this dis-
crepancy. As shown in Figure 3b and c, the individual
changes in TWL before and after BVA treatment in
NAN-190 or ketanserin pre-treated rats might be
divided into two distinct clusters; three responsive rats
and five non-responsive rats to either of the two antago-
nists. However, both of a systemic injection and an
intrathecal injection of MDL-72222 similarly blocked
the BVA anti-allodynic effect (Figure 3d). This result is
in consistent with the other studies showing that spinal
5-HT3 receptors have antinociceptive roles [43-45].
Thus, our data strongly suggest that spinal 5-HT3
receptors play an important role in the BVA-induced
anti-allodynic action in oxaliplatin-injected rats.
Conclusions
In conclusion, this study clearly demonstrates a key role of
the serotonergic inhibitory system in the relieving effect of
BVA on oxaliplatin-induced neuropathic cold allodynia,
and specifically, spinal 5-HT3 receptors are activated to
exert the anti-allodynic effect of BVA. These results provide
a basic evidence for the application of BVA as an alternative
therapeutic option for the management of oxaliplatin-
induced peripheral neuropathy and may raise the possibility
of the combinational use of BVA with well-known analge-
sics, such as morphine, gabapentin and antidepressants.
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